Quote:

---

"However in vitro, maraviroc can displace LL on the CCR5 receptor; it has higher affinity."

---

I can guess who that came from. They never tire of being wrong.

Quote:

---

Leronlimab IC50 did not appear significantly altered by previous or current exposure to maraviroc.
https://www.businesswire.com/news/home/202201...E-Subjects

---

Quote:

---

Current exposure to MVC was not associated with different PRO 140 activity (p=0.376)
https://www.natap.org/2020/CROI/croi_214.htm

---

Why someone might think that and a nice explanation by Dr. Jonas Sacha of a new receptor occupancy test if you read the whole paper.

Quote:

---

Maraviroc inhibits CCR5 internalization following ligand binding, and thus Maraviroc CCR5 RO is indirectly measured by a MIP-1β internalization assay where CCR5 RO is defined by the percentage of cell surface CCR5 that is not down-regulated following treatment with MIP-1β . This indirect method of measuring CCR5 RO results in background RO of approximately 25% , with reports of 120% CCR5 RO in peripheral blood CD4+ T cells from both Maraviroc-treated and -untreated rhesus macaques (39). These issues of extremely high background and overcalculation of CCR5 RO are major limitations of the MIP-1β internalization assay, especially when CCR5 RO is a critical parameter in studying CCR5-blocking agents.

https://www.frontiersin.org/articles/10.3389/...94638/full

---